ProCE Banner Series

Conference to Clinic: Expert Analysis of the Top Abstracts From the 2023 ASH Annual Meeting

Join us for this live, interactive webinar to hear experts discuss some of the most impactful abstracts presented during the ASH annual meeting and answer audience questions on the data. Full details on the available topics are provided below.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for healthcare professionals, nurses, pharmacists, and physician associates who care for patients with malignant or nonmalignant hematologic disorders.

All Events

Conference to Clinic: Expert Analysis of the Top Abstracts From the 2023 ASH Annual Meeting

Past Events

January

13

2024

8:30 AM - 4:35 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

ProCE Banner Faculty
Ian W. Flinn, MD, PhD

Director
Lymphoma Research Program
Sarah Cannon Research Institute
Program Director
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

ProCE Banner Faculty
Rami Komrokji, MD

Vice Chair of Malignant Hematology Department
Senior Member and Professor of Oncologic Sciences
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, Florida

ProCE Banner Faculty
Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

ProCE Banner Faculty
Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

ProCE Banner Faculty
Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

ProCE Banner Faculty
Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

ProCE Banner Faculty
George Yaghmour, MD

Associate Professor of Clinical Medicine
Associate Director of Allogeneic Bone Marrow Transplant
USC Norris Comprehensive Cancer Center
University of Southern California

Topics

Leukemias and Myelodysplastic syndrome (MDS)

Multiple Myeloma

Lymphomas

Myeloproliferative neoplasms (MPN)

Non-Malignant Hematology

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with malignant or nonmalignant hematologic disorders. 

Target Audience
This program is intended for healthcare professionals, nurses, pharmacists, and physician associates who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with malignant or nonmalignant hematologic disorders
  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders
  • Appraise how new trial findings might affect treatment of patients with malignant or nonmalignant hematologic disorders in the future

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

- 1.0 Leukemias and Myelodysplastic Syndrome (MDS)

- 1.0 Multiple Myeloma

- 1.0 Lymphomas

- 0.75 Myeloproliferative Neoplasms (MPN)

- 1.0 Non-Malignant Hematology

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.75 contact hours.

- 1.0 Leukemias and Myelodysplastic Syndrome (MDS)

- 1.0 Multiple Myeloma

- 1.0 Lymphomas

- 0.75 Myeloproliferative Neoplasms (MPN)

- 1.0 Non-Malignant Hematology

Continuing Pharmacy Education

CCO designates this continuing education activity for 4.75 contact hours (0.475 CEUs) of the Accreditation Council for Pharmacy Education. UAN specific to each topic.

- 1.0 Leukemias and Myelodysplastic Syndrome (MDS)- UAN: JA4008176-0000-24-033-L01-P

- 1.0 Multiple Myeloma - UAN: JA4008176-0000-24-031-L01-P

- 1.0 Lymphomas - UAN: JA4008176-0000-24-034-L01-P

- 0.75 Myeloproliferative Neoplasms (MPN) - UAN: JA4008176-0000-24-035-L01-P

- 1.0 Non-Malignant Hematology - UAN: JA4008176-0000-24-036-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

- 1.0 Leukemias and Myelodysplastic Syndrome (MDS)

- 1.0 Multiple Myeloma

- 1.0 Lymphomas

- 0.75 Myeloproliferative Neoplasms (MPN)

- 1.0 Non-Malignant Hematology

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.